Dexcom Becomes Team Novo Nordisk's Official CGM Partner, Releases Report Citing Three Type 2 Care Challenges Across Eight Countries

RBC Capital Maintains Outperform on DexCom, Raises Price Target to $105

ViCentra Presents Large-Scale Real-World Evidence Demonstrating Kaleido Insulin Patch Pump System Delivers Stable Glucose Control with Very Low Hypoglycemia

ViCentra announced real-world data from 3,918 adults showing its Kaleido insulin patch pump system achieved 72.2% median time in range with minimal hypoglycemia (0.21% time below 54 mg/dL) and low glycemic variability (28.7% coefficient of variation) across Germany, the Netherlands, and France. The system, integrated with Diabeloop's DBLG1 algorithm and Dexcom G6, demonstrated strong clinical performance in routine use with high user engagement.

The Insider Report: The Leaders Have Taken Off

Market Overview Stocks began their breakout to new all-time highs again, but it remains a highly selective environment. Only the Nasdaq hit a record high, as it finished up 2.06% on the week, and outperformed for the

Over 88% Of Wegovy Trial Participants Achieve Normal Liver Fat Levels, Novo Reports

Novo Nordisk's Wegovy significantly reduced liver fat in adults with obesity in a recent post hoc analysis, potentially lowering MASH risk.

Novo Announces Wegovy Liver Fat Reductions To Normal Levels In 9 Out Of 10 Adults With Obesity And Excess Liver Fat

NVO's Ozempic Outshines LLY's Mounjaro in Lowering Cardiovascular Risk

Novo's COMPETE SWITCH CV study found that patients who escalated their Ozempic dose to 2 mg had a 6% lower observed risk of major adverse cardiovascular events (MACE) compared to those who switched to Eli Lilly's Mounjaro. However, the study shows association rather than causation and did not evaluate safety outcomes.